Companies: 10,795·Total market cap: $144.5T
F-star Therapeutics, Inc.

F-star Therapeutics, Inc.

FSTXNASDAQHealthcare
$7.12
+$0.00(+0.00%)
Market Cap$156511128
P/E Ratio
52W High$7.12
52W Low$2.07

F-star Therapeutics, Inc.(FSTX)股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

fstx · 股价预测 · 5 位分析师(近3月)· FMP · 更新于 2023年12月4日

分析师评级与共识

基于过去 3 个月内 5 位华尔街分析师

SellBuy

Buy

5 位分析师

共识

评级分布

Strong Buy
0
Buy
3
Hold
2
Sell
0
Strong Sell
0
合计: 5 · 买入占比: 60.0%

12 个月目标价

High

$0.00

Consensus

$0.00

+0.0% upside

Low

$0.00

Median: $0 · Last Close: $7.12

F-star Therapeutics, Inc.(FSTX)的分析师共识为 Buy,基于过去 3 个月内 5 位华尔街分析师的评级。FSTX 的 12 个月平均目标价为 $0.00,相对当前价 $7.12 代表 +0.0% 的潜在上行空间。

短期股价预测

算法生成 · 每日更新

DatePredicted PriceChange
2026-06-10$7.485.00%

1-day model range: $7.36–$7.59. Peak: $7.59 (+5.00%).

长期股价预测

⚠️ 在满 252 个交易日历史(IPO/上市时间较短)前不展示长期预测;短期标签页仍可能显示模型输出。

基于技术分析的股价预测

14 项技术面信号(SMA×6 + EMA×6 + RSI + MACD)· EEAT 方法论透明

Market Sentiment

NEUTRAL

Based on 14 technical indicators

50%43%7%
7Buy
6Neutral
1Sell
RSI (14)76.7Overbought
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · FSTX · Jun 9, 2026

Simple Moving Average (SMA)
MA 5$6.31BUY
MA 10$5.97BUY
MA 20$5.37BUY
MA 50$0.00NEUTRAL
MA 100$0.00NEUTRAL
MA 200$0.00NEUTRAL
Current $FSTX · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$6.50BUY
EMA 10$6.05BUY
EMA 20$5.69BUY
EMA 50$0.00NEUTRAL
EMA 100$0.00NEUTRAL
EMA 200$0.00NEUTRAL
Current $FSTX · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:
HC Wainwright & Co.2022-07-15
Downgrade ↓
BuyNeutral
SVB Leerink2022-06-24
Downgrade ↓
OutperformPerform
SVB Leerink2022-05-11
Maintains
OutperformOutperform
HC Wainwright & Co.2022-03-17
Maintains
BuyBuy
SVB Leerink2021-08-17
Maintains
OutperformOutperform
SVB Leerink2021-07-08
Maintains
OutperformOutperform
B. Riley Securities2021-06-09
Maintains
BuyBuy
HC Wainwright & Co.2021-05-18
Maintains
BuyBuy
Oppenheimer2021-04-16
Maintains
OutperformOutperform
William Blair2021-04-08
Maintains
OutperformOutperform

Wall Street analysts have recently issued updated ratings on F-star Therapeutics, Inc. (FSTX) stock. Of the recent 10 rating actions, 0 were upgrades and 2 were downgrades. 5 analysts currently cover FSTX.

分析师推荐趋势

Buy ratings101
Hold ratings01↑ +1
Sell ratings00

FSTX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.

财务预测:EPS 与营收一致预期

Revenue This Year

Revenue Next Year

EPS This Year

EPS Next Year

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast FSTX EPS of $ for the current fiscal year, based on estimates from 0 analysts. The FSTX revenue forecast is for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

FSTX 股价预测由两类独立数据源支撑:来自 5 位华尔街分析师(S&P Global / FMP)的共识评级,以及基于历史日终价计算的技术分析。FSTX 的共识目标价为 $0.00(+0.0% 上行空间),分析师共识为 Buy。

FSTX 的短期预测(明日)为 $7.48(+5.00%)。

F-star Therapeutics, Inc. 在 NASDAQ 上市,代码 FSTX。FSTX 在 2027 年的整体展望偏积极,在覆盖分析师中约 60% 对应 Buy 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

常见问题

FSTX 预测 · 8 个问题

根据 5 位华尔街分析师,FSTX 的 12 个月平均目标价为 $0.00,最高 $0.00、最低 $0.00。若有图表,中位目标价可在上方查看。相对当前价 $7.12,隐含约 +0.0% 的上行空间。

FSTX 目标价FSTX 分析师目标价FSTX 12个月目标价目标价 FSTX

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.